U.S.-Israeli Airstrikes Target Iranian Pharmaceutical Company

On March 31, 2026, U.S. and Israeli airstrikes targeted the Tofigh Daru Research & Engineering Company in Tehran, a significant pharmaceutical facility responsible for producing anaesthetic and cancer medications. The Iranian government reported that the strikes resulted in extensive damage to the company's production and research units, which are crucial for the country's healthcare system. Tofigh Daru is owned by the Social Security Investment Company, a state-run entity, and plays a vital role in Iran's domestic drug production, particularly amid ongoing international sanctions that have severely limited access to foreign pharmaceuticals.

The HinduIran's Cancer Pharmaceutical Plant Hit by U.S.-Israeli AggressionNew York TimesIsrael Claims Targeted Iranian Facility Was Used for Chemical Weapons Development

The Israeli military asserted that the Tofigh Daru facility was involved in supplying materials for chemical weapons, specifically alleging that it provided fentanyl to the Organization of Defensive Innovation and Research (SPND), which is linked to Iran's military programs. Conversely, Iranian officials, including Foreign Minister Abbas Araghchi, condemned the strikes as blatant attacks on civilian infrastructure, emphasizing that the facility was primarily engaged in producing essential medical supplies. Araghchi characterized the Israeli actions as "openly and unashamedly bombing pharmaceutical companies," asserting that such strikes violate international humanitarian law.

Israel Claims Targeted Iranian Facility Was Used for Chemical Weapons DevelopmentNew York TimesIran will ‘severely punish’ Israel for attacking pharmaceutical company: FMIran's Cancer Pharmaceutical Plant Hit by U.S.-Israeli Aggression

The attack on Tofigh Daru has raised significant concerns regarding the humanitarian impact on Iran's population, particularly cancer patients who rely on the facility for treatment. Experts have noted that the destruction of a pharmaceutical production site constitutes a severe escalation in the conflict, transforming essential healthcare into a target of military aggression. Esfandyar Batmanghelidj, head of the Bourse & Bazaar Foundation, highlighted that the primary damage from such strikes is civilian, arguing that even if dual-use materials are involved, the destruction of a healthcare facility cannot be justified.

New York Times

Iran's leadership has vowed to retaliate against the strikes, with Araghchi warning that the Iranian Armed Forces would "severely punish" those responsible. The Iranian government has framed the attack as part of a broader campaign of aggression by the U.S. and Israel, which has included strikes on various civilian and military targets since the onset of hostilities on February 28, 2026. This ongoing conflict has already resulted in significant casualties, including the assassination of high-ranking Iranian officials.

Iran will ‘severely punish’ Israel for attacking pharmaceutical company: FM

There are conflicting narratives regarding the nature of the Tofigh Daru facility. While Israel claims it was involved in military activities under the guise of a civilian operation, Iranian officials maintain that it was solely focused on pharmaceutical production. This discrepancy highlights the complexities of the situation and the challenges in assessing the legality and morality of such military actions.

New York Times

The airstrikes on Tofigh Daru represent a troubling shift in the U.S.-Israeli military strategy, moving from traditional military targets to critical civilian infrastructure. This development not only exacerbates the humanitarian crisis in Iran but also raises serious questions about the adherence to international law in conflict situations. As tensions continue to escalate, the potential for further retaliatory actions from Iran remains high, indicating a prolonged period of instability in the region.

Iran's Cancer Pharmaceutical Plant Hit by U.S.-Israeli Aggression